Rob Quinn


Rob is CFO at BenevolentAI. His  career has been dedicated to life sciences and the advancement of innovative medicines. He holds both a PhD in Biochemistry, from the University of Manchester, and a chartered accountancy qualification. Rob has served roles of increasing responsibility at Deloitte, GSK and, most recently, as CFO of Silence Therapeutics plc where he played a major role in the transformation of the business. In his time as CFO, Silence listed on Nasdaq, secured over $100m through licensing deals and had a 10x increase in valuation.